Literature DB >> 26507866

Prevalence of emm types and antimicrobial susceptibility of Streptococcus dysgalactiae subsp. equisimilis in Austria.

Eva Leitner1, Ines Zollner-Schwetz2, Gernot Zarfel1, Lilian Masoud-Landgraf1, Michael Gehrer1, Ute Wagner-Eibel1, Andrea J Grisold1, Gebhard Feierl1.   

Abstract

OBJECTIVES: An increase of severe infections caused by Streptococcus dysgalactiae subsp. equisimilis (SDSE) similar to infections caused by Streptococcus pyogenes has been reported over the last years. Little is known about infections with SDSE in Austria. Therefore, we investigated a collection of 113 SDSE invasive and non-invasive isolates from different infection sites and type of infections as well as patients' characteristics.
METHODS: The isolates were phenotypically identified and emm typed using the enlarged emm database from the Centers for Disease Control and Prevention. Additionally, 13 antimicrobial agents were tested using EUCAST guidelines and virulence genes were investigated.
RESULTS: Severe SDSE infections were most common in elderly men with underlying diseases especially diabetes mellitus. With VitekMS identification of SDSE isolates was successful to the species level only. Emm typing revealed 24 different emm types, one new type and one new subtype. StG485, stG6, stC74a, stG643, and stG480 were the predominant types in this study, stC74a and stG652 in invasive infections and stG643, stC74a and stG485 in non-invasive infections. Resistance was observed to tetracycline (62%), macrolides (13%) with one M phenotype, and clindamycin (12%) presenting 6 constitutive MLS(B) phenotypes and 8 inducible MLS(B) phenotypes. Levofloxacin resistance was detected only in one isolate. All isolates tested for virulence genes were positive for scpA, ska, saga and slo. Superantigenic genes were negative except speG(dys) (positive 17/34; 50%).
CONCLUSION: This paper presents the first report of SDSE infections in Austria. Severe SDSE infections were found mainly in elderly men with underlying diseases. SDSE isolates demonstrated substantial emm type diversity without association with infections site or invasiveness. Analysis of virulence genes showed no significant difference between invasive and non-invasive infections.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility; Austria; Emm types; Streptococcus dysgalactiae subsp. equisimilis; Virulence genes; Vitek2; VitekMS

Mesh:

Substances:

Year:  2015        PMID: 26507866     DOI: 10.1016/j.ijmm.2015.10.001

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  4 in total

1.  Streptococcus dysgalactiae subsp. equisimilis from invasive and non-invasive infections in Spain: combining epidemiology, molecular characterization, and genetic diversity.

Authors:  Beatriz Rojo-Bezares; Laura Toca; José Manuel Azcona-Gutiérrez; Nerea Ortega-Unanue; Paula Toledano; Yolanda Sáenz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-03       Impact factor: 3.267

2.  Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012-2014.

Authors:  Sylvain A Lother; Walter Demczuk; Irene Martin; Michael Mulvey; Brenden Dufault; Philippe Lagacé-Wiens; Yoav Keynan
Journal:  Emerg Infect Dis       Date:  2017-07       Impact factor: 6.883

3.  Emergence of a Streptococcus dysgalactiae subspecies equisimilis stG62647-lineage associated with severe clinical manifestations.

Authors:  Oddvar Oppegaard; Haima Mylvaganam; Steinar Skrede; Paul Christoffer Lindemann; Bård Reiakvam Kittang
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

4.  Molecular Epidemiological Features and Antibiotic Susceptibility Patterns of Streptococcus dysgalactiae subsp. equisimilis Isolates from Korea and Japan.

Authors:  Sunjoo Kim; Jung Hyun Byun; Hyunwoong Park; Jaehyeon Lee; Hye Soo Lee; Haruno Yoshida; Akiyoshi Shibayama; Tomohiro Fujita; Yuzo Tsuyuki; Takashi Takahashi
Journal:  Ann Lab Med       Date:  2018-05       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.